Clinical Trial Detail

NCT ID NCT00923013
Title Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

hairy cell leukemia

Therapies

Cladribine

Rituximab

Cladribine + Rituximab

Age Groups: adult senior

No variant requirements are available.